Article

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized Biologics

2026-03-27

Abstract excerpt

Therapeutic monoclonal antibodies have transformed treatment across cancer, autoimmune disorders, and infectious diseases, yet their clinical utility remains challenged by immunogenicity and the resulting formation of anti-drug antibodies (ADAs), which can alter pharmacokinetics, neutralise therapeutic activity, and cause serious adverse events. This review synthesises current evidence on the mechanisms, predictio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9777e0a6-8bf0-5ba9-98b4-11a403c2324a
DOI: 10.20944/preprints202603.2174.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsDOI 10.20944/preprints202603.2174.v1Read

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable PatientsSemantic proximity Read

Antibody immunogenicity prediction and optimization with ImmunoSeqSemantic proximity Read

Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity Read

Sagacious Epitope Selection for Vaccines, and Both Antibody-Based Therapeutics and Diagnostics: Tips From Virology and Oncology<strong> </strong>Semantic proximity Read

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodiesSemantic proximity Read

MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humansSemantic proximity Read

Mechanism of Action and Pharmacokinetics of Approved Bispecific AntibodiesSemantic proximity Read

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies.Semantic proximity Read

Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profilingSemantic proximity Read

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies.Semantic proximity Read

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopesSemantic proximity Read

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeuticsSemantic proximity Read